Aprea Therapeutics, Inc. Banner Image

Aprea Therapeutics, Inc. has reached its limit for free report views

Work for Aprea Therapeutics, Inc.? Upgrade Your Profile and unlock all your annual reports.

Aprea Therapeutics, Inc.

  • Ticker APRE
    Exchange NASDAQ More
  • Industry Biotechnology More
  • Sector Healthcare More
Aprea Therapeutics, Inc. Logo Image
  • 11-50 Employees
  • Based in Boston, Massachusetts
Aprea Therapeutics, Inc. is a biopharmaceutical company headquartered in Boston, Massachusetts with research facilities in Stockholm, Sweden, focused on developing and commercializing novel cancer therapeutics that reactivate mutant tumor suppressor protein, p53. The Company’s lead product candidate is APR-246 (eprenetapopt), a small molecule in clinical development for hematologic malignanciesMore, including myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). APR-246 has received Breakthrough Therapy, Orphan Drug and Fast Track designations from the FDA for MDS, and Orphan Drug designation from the European Commission for MDS, AML and ovarian cancer.
Aprea Therapeutics, Inc.

Most Recent Annual Report

Aprea Therapeutics, Inc. MOST RECENT 2019 Annual Report and Form 10K

Report Locked. Aprea Therapeutics, Inc. has reached its limit for free report views.